FDA Streamlines Monitoring for Amgen's Imdelltra Infusions

The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen's Imdelltra, a targeted immunotherapy designed to treat extensive-stage small cell lung cancer (ES-SCLC).

The revised guidance reduces the recommended monitoring time for patients with ES-SCLC after their first two infusions from 22-24 hours to six-eight hours in an appropriate healthcare setting.

This change is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy, and it replaces the previous requirement for extended observation periods.

For subsequent doses, the monitoring requirements remain unchanged: three-four hours for Cycles 3-4, and two hours for Cycle 5 and beyond.